Literature DB >> 21162712

Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide.

Kevin R W Ngoei1, Bruno Catimel, Nicole Church, Daisy S Lio, Con Dogovski, Matthew A Perugini, Paul M Watt, Heung-Chin Cheng, Dominic C H Ng, Marie A Bogoyevitch.   

Abstract

An improved understanding of the roles of protein kinases in intracellular signalling and disease progression has driven significant advances in protein kinase inhibitor discovery. Peptide inhibitors that target the kinase protein substrate-binding site have continued to attract attention. In the present paper, we describe a novel JNK (c-Jun N-terminal kinase) inhibitory peptide PYC71N, which inhibits JNK activity in vitro towards a range of recombinant protein substrates including the transcription factors c-Jun, ATF2 (activating trancription factor 2) and Elk1, and the microtubule regulatory protein DCX (doublecortin). Analysis of cell culture studies confirmed the actions of a cell-permeable version of PYC71 to inhibit c-Jun phosphorylation during acute hyperosmotic stress. The analysis of the in vitro data for the kinetics of this inhibition indicated a substrate-inhibitor complex-mediated inhibition of JNK by PYC71N. Alanine-scanning replacement studies revealed the importance of two residues (PYC71N Phe9 or Phe11 within an FXF motif) for JNK inhibition. The importance of these residues was confirmed through interaction studies showing that each change decreased interaction of the peptide with c-Jun. Furthermore, PYC71N interacted with both non-phosphorylated (inactive) JNK1 and the substrate c-Jun, but did not recognize active JNK1. In contrast, a previously characterized JNK-inhibitory peptide TIJIP [truncated inhibitory region of JIP (JNK-interacting protein)], showed stronger interaction with active JNK1. Competition binding analysis confirmed that PYC71N inhibited the interaction of c-Jun with JNK1. Taken together, the results of the present study define novel properties of the PYC71N peptide as well as differences from the characterized TIJIP, and highlight the value of these peptides to probe the biochemistry of JNK-mediated substrate interactions and phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21162712     DOI: 10.1042/BJ20101244

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  10 in total

1.  Metabolism of peptide reporters in cell lysates and single cells.

Authors:  Angela Proctor; Qunzhao Wang; David S Lawrence; Nancy L Allbritton
Journal:  Analyst       Date:  2012-02-07       Impact factor: 4.616

2.  Structural mechanisms of allostery and autoinhibition in JNK family kinases.

Authors:  John D Laughlin; Jerome C Nwachukwu; Mariana Figuera-Losada; Lisa Cherry; Kendall W Nettles; Philip V LoGrasso
Journal:  Structure       Date:  2012-11-08       Impact factor: 5.006

Review 3.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 4.  JNK signaling as a target for anticancer therapy.

Authors:  Kamal S Abdelrahman; Heba A Hassan; Salah A Abdel-Aziz; Adel A Marzouk; Atsushi Narumi; Hiroyuki Konno; Mohamed Abdel-Aziz
Journal:  Pharmacol Rep       Date:  2021-03-12       Impact factor: 3.024

5.  WD40-repeat protein 62 is a JNK-phosphorylated spindle pole protein required for spindle maintenance and timely mitotic progression.

Authors:  Marie A Bogoyevitch; Yvonne Y C Yeap; Zhengdong Qu; Kevin R Ngoei; Yan Y Yip; Teresa T Zhao; Julian I Heng; Dominic C H Ng
Journal:  J Cell Sci       Date:  2012-08-16       Impact factor: 5.285

6.  Opposing roles for JNK and Aurora A in regulating the association of WDR62 with spindle microtubules.

Authors:  Nicholas R Lim; Yvonne Y C Yeap; Teresa T Zhao; Yan Y Yip; Shu C Wong; Dan Xu; Ching-Seng Ang; Nicholas A Williamson; Zhiheng Xu; Marie A Bogoyevitch; Dominic C H Ng
Journal:  J Cell Sci       Date:  2015-02-01       Impact factor: 5.285

7.  Enzyme kinetics and interaction studies for human JNK1β1 and substrates activating transcription factor 2 (ATF2) and c-Jun N-terminal kinase (c-Jun).

Authors:  Mariana Figuera-Losada; Philip V LoGrasso
Journal:  J Biol Chem       Date:  2012-02-17       Impact factor: 5.157

Review 8.  Advances in Immunosuppressive Agents Based on Signal Pathway.

Authors:  Zhiqing Xu; Ming Chu
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

Review 9.  Selective inhibitors for JNK signalling: a potential targeted therapy in cancer.

Authors:  Qinghua Wu; Wenda Wu; Vesna Jacevic; Tanos C C Franca; Xu Wang; Kamil Kuca
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

10.  Selective inhibition of JNK located on mitochondria protects against mitochondrial dysfunction and cell death caused by endoplasmic reticulum stress in mice with LPS‑induced ALI/ARDS.

Authors:  Congcong Li; Debin Ma; Yan Chen; Wei Liu; Faguang Jin; Liyan Bo
Journal:  Int J Mol Med       Date:  2022-05-06       Impact factor: 5.314

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.